Literature DB >> 23231449

Coordination of late gene transcription of human cytomegalovirus with viral DNA synthesis: recombinant viruses as potential therapeutic vaccine candidates.

Hiroki Isomura1, Mark F Stinski.   

Abstract

INTRODUCTION: During productive infection, human cytomegalovirus (HCMV) genes are expressed in a temporal cascade, with temporal phases designated as immediate-early (IE), early, and late. The major IE (MIE) genes, UL123 and UL122 (IE1/IE2), play a critical role in subsequent viral gene expression and the efficiency of viral replication. The early viral genes encode proteins necessary for viral DNA replication. Following viral DNA replication, delayed-early and late viral genes are expressed which encode structural proteins for the virion. The late genes can be divided into two broad classes. At early times the gamma-1 or leaky-late class are expressed at low levels after infection and are dramatically upregulated at late times. In contrast, the gamma-2 or 'true' late genes are expressed exclusively after viral DNA replication. Expression of true late (gamma-2 class) viral genes is completely prevented by inhibition of viral DNA synthesis. AREAS COVERED: This review addresses the viral genes required for HCMV late gene transcription. Recombinant viruses that are defective for late gene transcription allow for early viral gene expression and viral DNA synthesis, but not infectious virus production. Since current HCMV prophylaxis is limited by several shortcomings, the use of defective recombinant viruses to induce HCMV cell-mediated and humoral immunity is discussed. EXPERT OPINION: HCMV DNA replication and late gene transcription are not completely linked. Viral-encoded trans-acting factors are required. Recombinant viruses proficient in MIE and early viral gene expression and defective in late gene expression may be an alternative therapeutic vaccine candidates for the induction of cell-mediated and humoral immunity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23231449     DOI: 10.1517/14728222.2013.740460

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  7 in total

1.  Transcription of true late (γ2) cytomegalovirus genes requires UL92 function that is conserved among beta- and gammaherpesviruses.

Authors:  Shinya Omoto; Edward S Mocarski
Journal:  J Virol       Date:  2013-10-16       Impact factor: 5.103

2.  The Epstein-Barr Virus BDLF4 Gene Is Required for Efficient Expression of Viral Late Lytic Genes.

Authors:  Takahiro Watanabe; Yohei Narita; Masahiro Yoshida; Yoshitaka Sato; Fumi Goshima; Hiroshi Kimura; Takayuki Murata
Journal:  J Virol       Date:  2015-07-22       Impact factor: 5.103

3.  Functional single-cell genomics of human cytomegalovirus infection.

Authors:  Marco Y Hein; Jonathan S Weissman
Journal:  Nat Biotechnol       Date:  2021-10-25       Impact factor: 54.908

4.  Human Cytomegalovirus Infection Elicits Global Changes in Host Transcription by RNA Polymerases I, II, and III.

Authors:  Christopher B Ball; Mrutyunjaya Parida; Ming Li; Benjamin M Spector; Gustavo A Suarez; Jeffery L Meier; David H Price
Journal:  Viruses       Date:  2022-04-09       Impact factor: 5.818

5.  Complete Genome and Molecular Characterization of a New Cyprinid Herpesvirus 2 (CyHV-2) SH-01 Strain Isolated from Cultured Crucian Carp.

Authors:  Jia Yang; Jinxuan Wen; Simin Xiao; Chang Wei; Fei Yu; Patarida Roengjit; Liqun Lu; Hao Wang
Journal:  Viruses       Date:  2022-09-17       Impact factor: 5.818

6.  Mapping the Human Herpesvirus 6B transcriptome.

Authors:  Annie Gravel; Wes Sanders; Éric Fournier; Arnaud Droit; Nathaniel Moorman; Louis Flamand
Journal:  J Virol       Date:  2021-02-24       Impact factor: 5.103

7.  Neutralizing Monoclonal Antibodies Reduce Human Cytomegalovirus Infection and Spread in Developing Placentas.

Authors:  Takako Tabata; Matthew Petitt; June Fang-Hoover; Daniel C Freed; Fengsheng Li; Zhiqiang An; Dai Wang; Tong-Ming Fu; Lenore Pereira
Journal:  Vaccines (Basel)       Date:  2019-09-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.